Search

APD668

APD668 is a novel, highly potent and orally active glucose-dependent insulinotropic receptor (GDIR) agonist intended to more efficiently stimulate insulin release by beta cells in response to elevated

Xaliproden

Aplaviroc

A spiro-diketo-piperazine; a potent noncompetitive allosteric antagonist of the CCR5 receptor with concomitantly potent antiviral effects for HIV-1.

Amniotic Epithelial Cells

Amniotic epithelial cells (AEC) are multipotent stem-like cells derived from the basement collagenous membrane of the human amnion, the layer of the placenta closest to the fetus. These cells are potential candidates for allogeneic cell ...

GR270773

infusion between healthy adults and those with damaged livers) and NCT00089986 (completed with results, treatment of suspected or confirmed gram-negative severe sepsis in adults, comparing GR270773 with a

(S)-Warfarin

S-warfarin is 2-5 times more potent than the R-isomer in producing an anticoagulant response.[A7166] … Warfarin consists of a racemic mixture of two active enantiomers—R- and S- forms—each of which is cleared by different pathways.

Asundexian

Asundexian is under investigation in clinical trial NCT05686070 (A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk … Transient Ischemic Attack, a So-called Mini Stroke).

Autologous Non-Hematopoietic Peripheral Blood Stem Cells

Autologous non-hematopoietic peripheral blood stem cells have been created into a formulation for use in a clinical trial (NCT04473170) by the Abu Dhabi Stem Cells Center.

Aldafermin

Aldafermin is under investigation in clinical trial NCT03912532 (Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center

ORG-34517

It has potential to treat a number of diseases such as Cushing’s disease, hypertension, diabetes, glaucoma etc, in which the activity of metabolites corticosterone and cortisol is high.